Equipoise: asking the right questions for clinical trial design

被引:24
作者
Joffe, Steven [1 ]
Miller, Franklin G. [2 ]
机构
[1] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA
[2] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA
关键词
BREAST-CANCER; THERAPY; ETHICS; TAMOXIFEN; CHEMOTHERAPY; ONDANSETRON; LETROZOLE; WOMEN; RISK;
D O I
10.1038/nrclinonc.2011.211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Randomized controlled trials (RCTs) are central to evidence-based clinical and health-policy decisions. However, RCTs highlight the tension between the therapeutic obligations of the physician and the scientific obligations of the investigator. Clinical equipoise, defined as honest professional disagreement among expert clinicians about the preferred treatment, is often cited as the solution to this RCT dilemma. Nevertheless, there are numerous practical and conceptual problems with the notion of equipoise. These problems include its mistaken imposition of therapeutic norms on the scientific enterprise of research, the difficulty of knowing when a state of equipoise exists, the susceptibility of expert judgment to bias and weak evidence, and its inability to support evidence necessary for health-policy decisions. An alternate approach to risk-benefit assessment that is congruent with the scientific purpose of RCTs can better guide ethical evaluation of these trials, as discussed in this Perspective.
引用
收藏
页码:230 / 235
页数:6
相关论文
共 36 条
[1]  
[Anonymous], 1974, Medical Experimentation: Personal Integrity and Social Policy
[2]  
[Anonymous], 2002, INT ETH GUID BIOM RE
[3]  
[Anonymous], 2003, NY TIMES, V4
[4]  
[Anonymous], 1978, The Belmont report: Ethical principles and guidelines for the protection of human subjects of research
[5]   EFFICACY OF ORAL ONDANSETRON IN THE PREVENTION OF EMESIS IN OUTPATIENTS RECEIVING CYCLOPHOSPHAMIDE-BASED CHEMOTHERAPY [J].
BECK, TM ;
CIOCIOLA, AA ;
JONES, SE ;
HARVEY, WH ;
TCHEKMEDYIAN, NS ;
CHANG, A ;
GALVIN, D ;
HART, NE .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (06) :407-413
[6]   Letrozole after tamoxifen for breast cancer - What is the price of success? [J].
Bryant, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1855-1857
[7]   What are the implications of optimism bias in clinical research? [J].
Chalmers, I ;
Matthews, R .
LANCET, 2006, 367 (9509) :449-450
[8]   Effect of awareness of a randomized controlled trial on use of experimental therapy [J].
Clark, WF ;
Garg, AX ;
Blake, PG ;
Rock, GA ;
Heidenheim, AP ;
Sackett, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (10) :1351-1355
[9]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[10]   Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy [J].
DiBenedetto, J ;
Cubeddu, LX ;
Ryan, T ;
Kish, JA ;
Sciortino, D ;
Beall, C ;
Eisenberg, PD ;
Henderson, C ;
Griffin, D ;
Wentz, A .
CLINICAL THERAPEUTICS, 1995, 17 (06) :1091-1098